Taxit trial leuven

Allowing trough level to go too low results in poor disease control, while allowing it to go too high increases the risk of immunosuppressive and other side effects eg, antibody formation. A total of of patients completed the study. The trough-level—based algorithm clearly improves drug level maintenance compared with clinically driven dosing.

It forecasts that the air taxi market will see a compound annual growth rate CAGR of The sector is expected to be initially dominated by hybrid, piloted vehicles, with electric air taxis making their debut after , followed by autonomous aerial vehicles from While COVID may delay some developments in the short-term, management consultancy Roland Berger recently concluded it will have little long-term impact on the growth of the UAM market.

It expects , passenger drones to be in operation by Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. The cookie is used to store the user consent for the cookies in the category "Analytics". The cookie is used to store the user consent for the cookies in the category "Other.

The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is used to store the user consent for the cookies in the category "Performance". It does not store any personal data. Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. J Crohns Colitis ; 7 : — Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.

Gastroenterology ; : — Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol ; 12 : — Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol ; 12 : 80 — 4. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.

Inflamm Bowel Dis ; 19 : — Lancet ; : — 9. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut ; 63 : 7. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol ; : — 9. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.

Curr Gastroenterol Rep ; 16 : Ben-Horin S , Chowers Y. Nat Rev Gastroenterol Hepatol ; 11 : — Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis ; 18 : — 9. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

Gastroenterology ; : — 8. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther ; 39 : — Clin Gastroenterol Hepatol. Published Online First: 24 July Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.

J Immunol Methods ; : — Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics ; 53 : — Antibodies as carrier proteins. Pharm Res ; 15 : — 6. Gastroenterology ; : S — Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.

Inflamm Bowel Dis ; 16 : — Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med ; : — A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol ; 11 : — Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects.

Ann Rheum Dis ; 74 : 8. J Crohns Colitis ; 6 : S6. Log in using your username and password For personal accounts OR managers of institutional accounts. Forgot your log in details? Register a new account? Forgot your user name or password? Search for this keyword. Advanced search.

Log in via Institution. Email alerts.